Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluate the benefit of using liposomal bupivicaine in lumbar laminectomies in terms of length of stay, IV narcotic use, 30-day narcotic use, visual analog score (VAS) and 30-day readmissions
Recent evidence suggests the use of liposomal bupivicaine (LB) in lumbar spine surgery shortens length of hospital stay and overall post-operative narcotic use. Studies have shown its utility in single level microdiscectomies and lumbar fusions, but there have been no publications regarding lumbar laminectomies and associated outcomes with LB. The investigators' hypothesis is that LB will significantly shorten inpatient stays as well as overall narcotic usage in single, double or multi-level lumbar laminectomies.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Liposomal Bupivicaine | Active Comparator | Treatment with liposomal bupivicaine |
|
| Standard Local Anesthestic | Active Comparator | Treatment with Standard Local Anesthestic |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Liposomal bupivacaine | Drug | Injection of either liposomal bupivicaine or standard local anesthetic during surgical procedure. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall length of hospital stay from hospital admission to hospital discharge | Length of stay will be measured in hours | From date of hospital admission until date of hospital discharge, assessed up to 2 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| IV narcotic usage | Tracked by patient's electronic medical record | From date of hospital admission until date of hospital discharge, assessed up to 2 weeks. |
| 30-day narcotic usage | Narcotic usage will be assessed via state narcotic databases. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jens-Peter Witt, MD, PhD | Contact | 303-724-2306 | peter.witt@cuanschutz.edu | |
| Akal Sethi, MD | Contact | 303-724-1995 | akal.sethi@cuanschutz.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Colorado Anschutz Medical Campus | Recruiting | Aurora | Colorado | 80045 | United States |
There is no plan to share IPD.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D013130 | Spinal Stenosis |
| ID | Term |
|---|---|
| D013122 | Spinal Diseases |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
Double blinded, randomized
Not provided
Not provided
The PI, co-Investigators, and clinicians will be blinded to the patient's treatment arm. The pharmacist will be unblinded.
|
| 30-day post surgery |
| Change in Visual Analog Pain scale scores | The scale is called the Visual Analog Pain scale. This scale provides a measure of the patient's reported level of pain . Patients will be asked to rate their pain level using the Visual Analog Pain scale. This scale uses numbers, 1-10, with 1 being no pain and 10 being the worst pain. It also uses faces depicting no pain up to the worst pain. Lower reported scores indicate the patient has little to no pain, which is desirable. | Screening, Day of Procedure, Prior to Hospital Discharge (Post-op, Up to 2 weeks), Up to 30-days post-surgery (Follow-Up#1) and up to 12-months post-op follow up |
| 30-day readmission rates | Occurrences of readmission will be tracked by patient's electronic medical record | Day 30 |